Prosecution Insights
Last updated: April 19, 2026
Application No. 17/791,684

COMPLEXES OF N-HETEROCYCLIC CARBENES FOR TRANSITION METAL CATALYSIS

Non-Final OA §112
Filed
Jul 08, 2022
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rutgers The State University Of New Jersey
OA Round
3 (Non-Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
88%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
553 granted / 740 resolved
+14.7% vs TC avg
Moderate +14% lift
Without
With
+13.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
52 currently pending
Career history
792
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 740 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/18/2026 has been entered. As filed, claims 1, 2, 5, 7, and 10-15 are pending; claims 16, 17, 20, 21, 25, and 26 are withdrawn; and claims 3, 4, 6, 8, 9, 18, 19, and 22-24 are cancelled. Response to Amendments/Remarks Applicant’s amendments/remarks, filed 2/18/2026, with respect to claims 1, 2, 5, and 7-15, have been fully considered and are entered. The status for each rejection in the previous Office Action is set out below. The § 102(a)(1) rejection of claims 1, 2, 5, 7, 8, and 10-15 by Rubio-Perez is withdrawn per amendments and cancellation of claim 8. The § 102(a)(1) rejection of claims 1, 2, 5, 7-9, 11, 12, 14, and 15 by Hanley is withdrawn per amendments and cancellation of claims 8 and 9. The claim objection of claims 1, 11, and 12 is withdrawn per amendments. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5, 7, 10, and 13-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim recites the phrase, “wherein the optional substitution comprises at least one group. . .”, wherein the transitional phrase, “comprises”, is an open-ended language and therefore include additional subject matter that is not described in the instant specification and is not particularly pointed out or distinctly claimed. The identity of the additional atoms or groups is unknown and how to determine the identity of the additional atoms or groups is not pointed out or distinctly claimed. The term, “compound”, contradicts the open language "comprises." A "compound" is defined as a substance whose molecules consist of unlike elements and whose constituents cannot be separated by physical means (see Grant & Hackh's Chemical Dictionary (5th Ed. 1987) at page 148). By contrast, a composition is defined as elements or compounds forming a material or produced from it by analysis. Id. In other words, a compound is a molecule with more than one element, and a composition is a mixture of two or more compounds or molecules. The transitional term "comprising" is synonymous with "including", "containing", and "characterized by". "Comprising" is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997) (“Comprising” is a term of art used in claim language which means that the named elements are essential, but other elements may be added and still form a construct within the scope of the claim.); Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986); In re Baxter, 656 F.2d 679, 686, 210 USPQ 795, 803 (CCPA 1981); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948) (“comprising” leaves “the claim open for the inclusion of unspecified ingredients even in major amounts”). Thus, a “compound" is singular and requires a definite chemical formula, and the open-ended term "comprises" does not exclude unrecited elements. Furthermore, “comprising”, used in conjunction with “compound” fails to articular exactly what subject matter is excluded from the claim scope of compounds, thereby rendering the scope of claim 1 indefinite. Regarding claims 5, 7, 10, and 13-15, these claims are directly or indirectly dependent of claim 1, and they failed to correct the indefiniteness issue of claim 1, which rendered these claims indefinite. Claim Objections Claim 11 is objected to because of the following informalities: Regarding claim 11, the claim recites the phrase, “CH(2-Np)2”, which contains abbreviation, and the abbreviation needs to be spelled out in their entirety because this is the first time that 2-Np appears in the claim, and they must be defined. Appropriate correction is required. Claim 13 objected to under 37 CFR 1.75 as being a substantial duplicate of claim 1. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Both claims are drawn to n=2. Allowable Subject Matter Claims 2 and 12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Compact Prosecution The Examiner finds that withdrawn claims 25 and 26 would not be eligible for rejoinder once claims 1, 2, 5, 7, and 10-15 are found to be allowable. See MPEP 821.04. Accordingly, the Examiner would suggest that the Applicant cancel claims 25 and 26. Conclusion Claims 1, 5, 7, 10, and 13-15 are rejected. Claims 2 and 11-13 are objected. Claims 16, 17, 20, 21, 25, and 26 are withdrawn. Claims 3, 4, 6, 8, 9, 18, 19, and 22-24 are cancelled. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jul 08, 2022
Application Filed
Jun 29, 2025
Non-Final Rejection — §112
Sep 19, 2025
Response Filed
Nov 16, 2025
Final Rejection — §112
Feb 18, 2026
Request for Continued Examination
Feb 24, 2026
Response after Non-Final Action
Mar 20, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595225
METHOD FOR PRODUCING ASYMMETRIC LINEAR CARBONATE
2y 5m to grant Granted Apr 07, 2026
Patent 12582632
INHIBITION OF NEUROLOGICAL INJURIES DUE TO INFECTIONS VIA ADMINISTRATION OF BUTANETAP AND ANALOGS THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12571801
Tandem Activity-Based Sensing and Labeling Strategy for Reactive Oxygen Species Imaging
2y 5m to grant Granted Mar 10, 2026
Patent 12552792
SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME
2y 5m to grant Granted Feb 17, 2026
Patent 12552782
Analogs of Nitrofuran Antibiotics to Combat Resistance
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
88%
With Interview (+13.8%)
2y 7m
Median Time to Grant
High
PTA Risk
Based on 740 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month